Loading...
Market
Which neurodegenerative condition will Sangamo and Genentech target first in their partnership by December 31, 2024?
2
Resolution / Starting Odds
Alzheimer's Disease • 25%
Parkinson's Disease • 25%
Huntington's Disease • 25%
Other • 25%
Official announcements from Sangamo Therapeutics or Genentech
Story
Sangamo and Genentech Partner on $50M Upfront, $1.9B Genomic Medicines Deal
Aug 6, 2024, 12:27 PM
Sangamo Therapeutics has announced a global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. The deal includes $50 million in near-term upfront license fees and milestone payments, with potential development and commercial milestone payments of up to $1.9 billion. The agreement involves the use of Sangamo's ZF-repressors and STAC-BBB AAV delivery systems targeting tau and another undisclosed neurodegenerative condition. The tau-repressor therapy was previously part of a 2020 partnership with Biogen. This partnership aims to advance the development of genomic medicines for conditions such as Alzheimer's disease. The cash-strapped Sangamo expects this deal to extend its runway.
View original story
Similar markets
Cancer • 25%
Infectious Diseases • 25%
Autoimmune Diseases • 25%
Other • 25%
Huntington's Disease • 25%
ALS • 25%
Duchenne Muscular Dystrophy • 25%
Other • 25%
Respiratory drug • 25%
Immunology drug • 25%
Vaccine • 25%
Other • 25%
Cancer • 25%
Cardiovascular disease • 25%
Neurological disorder • 25%
Other • 25%
Positive • 25%
Negative • 25%
Neutral • 25%
Not Reported • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Merck • 25%
Other • 25%
Diabetes • 25%
Obesity • 25%
Heart Disease • 25%
Chronic Pain • 25%
Cancer • 25%
Autoimmune disorders • 25%
Infectious diseases • 25%
Other • 25%
File an appeal • 25%
Submit new data • 25%
Withdraw application • 25%
Other • 25%
Cardiovascular • 25%
Oncology • 25%
Neurology • 25%
Other • 25%